A new sensitive pcr assay for one-step detection of 12 idh1/2 mutations in glioma

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Catteau, Aurélie ^a   Girardi, Hélène ^a   Monville, Florence ^a   Poggionovo, Cécile ^a   Carpentier, Sabrina ^a   Frayssinet, Véronique ^a   Voss, Jesse ^c   Jenkins, Robert ^c   Boisselier, Blandine ^b   Mokhtari, Karima ^b   Sanson, Marc ^b   Peyro Saint Paul, Hélène ^a   Giannini, Caterina ^c  

^a Qiagen Marseille   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c MAYO CLINIC   (United States)

Author keywords

Glioma; IDH1 2; Quantitative real time PCR

Indexed keywords

IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; CLINICAL TRIAL; FEMALE; GENETICS; GLIOMA; HUMAN; INFORMATION PROCESSING; MALE; MULTICENTER STUDY; MUTATION; POLYMERASE CHAIN REACTION; PROCEDURES; REPRODUCIBILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; DATASETS AS TOPIC; FEMALE; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MUTATION; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84921670101     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-2-58     Document Type: Article

References (38)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114(2):97-109. doi:10.1007/s00401-007-0243-4 10.1007/s00401-007-0243-4
2. Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R: Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 2013, 14(9):e370-e379. doi:10.1016/S1470-2045(13)70168-2 10.1016/S1470-2045(13)70168-2
3. Thomas L, Di Stefano AL, Ducray F: Predictive biomarkers in adult gliomas: the present and the future. Curr Opin Oncol 2013, 25(6):689-694. doi:10.1097/CCO.0000000000000002 10.1097/CCO.0000000000000002
4. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009, 118(4):469-474. doi:10.1007/s00401-009-0561-9 10.1007/s00401-009-0561-9
5. von Deimling A, Korshunov A, Hartmann C: The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 2011, 21(1):74-87. doi:10.1111/j.1750-3639.2010.00454.x 10.1111/j.1750-3639.2010.00454.x
6. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD: IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360(8):765-773. doi:10.1056/NEJMoa0808710 10.1056/NEJMoa0808710
7. Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, Harter PN, Jeibmann A, von Deimling A: Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol 2011, 121(2):241-252. doi:10.1007/s00401-010-0770-2 10.1007/s00401-010-0770-2
8. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010, 16(5):1597-1604. doi:10.1158/1078-0432.CCR-09-2902 10.1158/1078-0432.CCR-09-2902
9. Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ: IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009, 73(21):1792-1795. doi:10.1212/WNL.0b013e3181c34ace 10.1212/WNL.0b013e3181c34ace
10. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY: IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010, 75(17):1560-1566. doi:10.1212/WNL.0b013e3181f96282 10.1212/WNL.0b013e3181f96282
11. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M: Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009, 27(34):5743-5750. doi:10.1200/JCO.2009.23.0805 10.1200/JCO.2009.23.0805
12. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009, 27(35):5874-5880. doi:10.1200/JCO.2009.23.6497 10.1200/JCO.2009.23.6497
13. Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M: Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013, 81(17):1515-1522. doi:10.1212/WNL.0b013e3182a95680 10.1212/WNL.0b013e3182a95680
14. Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, Huse JT, Mehta MP, Curran WJ Jr: Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH. J Clin Oncol 2014, 32(8):783-790. doi:10.1200/JCO.2013.49.3726 10.1200/JCO.2013.49.3726
15. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, Shonka N, Gilbert MR, Sawaya R, Prabhu SS, Weinberg J, Lang FF, Aldape KD, Sulman EP, Rao G, McCutcheon IE, Cahill DP: IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 2014, 16(1):81-91. doi:10.1093/neuonc/not159 10.1093/neuonc/not159
16. Taylor JW, Chi AS, Cahill DP: Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management. Oncology (Williston Park) 2013, 27(6):504-514.
17. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, MellinghoffIK: An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013, 340(6132):626-630. doi:10.1126/science.1236062 10.1126/science.1236062
18. Borodovsky A, Salmasi V, Turcan S, Fabius AW, Baia GS, Eberhart CG, Weingart JD, Gallia GL, Baylin SB, Chan TA, Riggins GJ: 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget 2013, 4(10):1737-1747.
19. Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, Chan TA: Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget 2013, 4(10):1729-1736.
20. The Catalogue of Somatic Mutations in Cancer (COSMIC). [http://cancer.sanger.ac.uk/cancergenome/projects/cosmic]
21. Preusser M, Capper D, Hartmann C: IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clin Neuropathol 2011, 30(5):217-230.
22. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010, 20(1):245-254. doi:10.1111/j.1750-3639.2009.00352.x 10.1111/j.1750-3639.2009.00352.x
23. Preusser M, Wohrer A, Stary S, Hoftberger R, Streubel B, Hainfellner JA: Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol 2011, 70(8):715-723. doi:10.1097/NEN.0b013e31822713f0 10.1097/NEN.0b013e31822713f0
24. Wayne PA: Evaluation of detection capability for clinical laboratory measurement procedures; approved guideline. CLSI document EP17-A2 2012.
25. Wayne PA: Evaluation of precision performance of quantitative measurement methods; approved guidelines. CLSI document EP05-A2 2004.
26. Ida CM, Lambert SR, Rodriguez FJ, Voss JS, Mc Cann BE, Seys AR, Halling KC, Collins VP, Giannini C: BRAF alterations are frequent in cerebellar low-grade astrocytomas with diffuse growth pattern. J Neuropathol Exp Neurol 2012, 71(7):631-639. doi:10.1097/NEN.0b013e31825c448a 10.1097/NEN.0b013e31825c448a
27. Tsiatis AC, Norris Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, Murphy KM: Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 2010, 12(4):425-432. doi:10.2353/jmoldx.2010.090188S1525-1578(10)60082-7 10.2353/jmoldx.2010.090188
28. Angulo B, Garcia Garcia E, Martinez R, Suarez Gauthier A, Conde E, Hidalgo M, Lopez Rios F: Commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn 2010, 12(3):292-299. doi:10.2353/jmoldx.2010.090139S1525-1578(10)60063-3 10.2353/jmoldx.2010.090139
29. Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frenay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W: Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 2010, 17(9):1124-1133. doi:10.1111/j.1468-1331.2010.03151.x 10.1111/j.1468-1331.2010.03151.x
30. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Central Nervous System Cancers. 2014., 1: Available via. Accessed 14 Mar 2014 http://www.nccn.org
31. Bujko M, Kober P, Matyja E, Nauman P, Dyttus-Cebulok K, Czeremszynska B, Bonicki W, Siedlecki JA: Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients. Mol Diagn Ther 2010, 14(3):163-169. doi:10.2165/11537170-000000000-00000 10.1007/BF03256369
32. Boisselier B, Marie Y, Labussiere M, Ciccarino P, Desestret V, Wang X, Capelle L, Delattre JY, Sanson M: COLD PCR HRM: a highly sensitive detection method for IDH1 mutations. Hum Mutat 2010, 31(12):1360-1365. doi:10.1002/humu.21365 10.1002/humu.21365
33. Horbinski C, Kelly L, Nikiforov YE, Durso MB, Nikiforova MN: Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn 2010, 12(4):487-492. 10.2353/jmoldx.2010.090228 10.2353/jmoldx.2010.090228
34. Loussouarn D, Le Loupp AG, Frenel JS, Leclair F, Von Deimling A, Aumont M, Martin S, Campone M, Denis MG: Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int J Oncol 2012, 40(6):2058-2062. doi:10.3892/ijo.2012.1404
35. Setty P, Hammes J, Rothamel T, Vladimirova V, Kramm CM, Pietsch T, Waha A: A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. J Mol Diagn 2010, 12(6):750-756. doi:10.2353/jmoldx.2010.090237 10.2353/jmoldx.2010.090237
36. Meyer J, Pusch S, Balss J, Capper D, Mueller W, Christians A, Hartmann C, Von Deimling A: PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol 2010, 20(2):298-300. doi:10.1111/j.1750-3639.2009.00327.xBPA327 10.1111/j.1750-3639.2009.00327.x
37. van den Bent MJ, Hartmann C, Preusser M, Strobel T, Dubbink HJ, Kros JM, von Deimling A, Boisselier B, Sanson M, Halling KC, Diefes KL, Aldape K, Giannini C: Interlaboratory comparison of IDH mutation detection. J Neurooncol 2013, 112(2):173-178. doi:10.1007/s11060-013-1056-z 10.1007/s11060-013-1056-z
38. Gupta R, Flanagan S, Li CC, Lee M, Shivalingham B, Maleki S, Wheeler HR, Buckland ME: Expanding the spectrum of IDH1 mutations in gliomas. Mod Pathol 2013, 26(5):619-625. doi:10.1038/modpathol.2012.210 10.1038/modpathol.2012.210